These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

648 related items for PubMed ID: 18449422

  • 21. Type 1 von Willebrand disease due to reduced von Willebrand factor synthesis and/or survival: observations from a case series.
    Casonato A, Gallinaro L, Cattini MG, Sartorello F, Pontara E, Padrini R, Bertomoro A, Daidone V, Pagnan A.
    Transl Res; 2010 Apr; 155(4):200-8. PubMed ID: 20303469
    [Abstract] [Full Text] [Related]

  • 22. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease.
    Sharthkumar A, Greist A, Di Paola J, Winay J, Roberson C, Heiman M, Herbert S, Parameswaran R, Shapiro A.
    Haemophilia; 2008 May; 14(3):539-48. PubMed ID: 18312368
    [Abstract] [Full Text] [Related]

  • 23. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).
    Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill FG, Montgomery RR.
    Blood; 2008 May 15; 111(10):4979-85. PubMed ID: 18344424
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet H.
    Clin Appl Thromb Hemost; 2006 Jul 15; 12(3):277-95. PubMed ID: 16959681
    [Abstract] [Full Text] [Related]

  • 26. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ, Gadisseur A, Budde U, Berneman Z, van der Planken M, Schroyens W, van de Velde A, van Vliet H.
    Semin Thromb Hemost; 2005 Nov 15; 31(5):577-601. PubMed ID: 16276467
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.
    Cattaneo M, Simoni L, Gringeri A, Mannucci PM.
    Br J Haematol; 1994 Feb 15; 86(2):333-7. PubMed ID: 8199023
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
    Hanebutt FL, Rolf N, Loesel A, Kuhlisch E, Siegert G, Knoefler R.
    Haemophilia; 2008 May 15; 14(3):524-30. PubMed ID: 18284449
    [Abstract] [Full Text] [Related]

  • 33. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A, van der Planken M, Schroyens W, Berneman Z, Michiels JJ.
    Acta Haematol; 2009 May 15; 121(2-3):145-53. PubMed ID: 19506361
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. von Willebrand factor clearance - biological mechanisms and clinical significance.
    O'Sullivan JM, Ward S, Lavin M, O'Donnell JS.
    Br J Haematol; 2018 Oct 15; 183(2):185-195. PubMed ID: 30378120
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients.
    Keularts IM, Hamulyak K, Hemker HC, Béguin S.
    Thromb Haemost; 2000 Oct 15; 84(4):638-42. PubMed ID: 11057863
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.